ArticleJournal of geriatric cardiology : JGC2026
Real-time monitoring of in-hospital mortality risk in intensive care units heart failure patients using an extreme gradient boosting model.
Article in Journal of geriatric cardiology : JGC, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To develop and validate a machine learning (ML) model for real-time monitoring of in-hospital mortality (IHM) risk and identification of major risk factors in heart failure (HF) patients admitted to intensive care units (ICUs). Methods: Data from ICU HF patients were extracted from the multicenter eICU-Collaborative Research Database (eICU-CRD. External validation used MIMIC-IV and a real-world Chinese dataset (CHN-dataset). Daily measurements from MIMIC-IV patients staying ≥ 3 days formed a Daily Measurement (DM) dataset. After rigorous preprocessing and feature selection, five ML algorithms were trained and optimized using eICU-CRD data. Model performance was evaluated using AUC, sensitivity, specificity, and balanced accuracy. The optimal model was benchmarked against APACHE and SOFA scores. SHapley Additive exPlanations (SHAP) interpreted feature contributions. A Windows application was developed for clinical deployment. Results: XGBoost emerged as the optimal model (Final-ML model), which incorporated only 17 routinely collected clinical variables: age, non-invasive systolic blood pressure (NI-SBP), heart rate, respiratory rate, Glasgow Coma Scale eye opening score, white blood cell count (WBC), creatinine, bicarbonate, red cell distribution width (RDW), platelet count, glucose, calcium, mean corpuscular hemoglobin concentration (MCHC), sodium, mean corpuscular volume, red blood cell count, and potassium. It achieved high AUCs: 0.876 (95%CI: 0.836-0.915; eICU-CRD test data), 0.932 (95%CI: 0.921-0.942; MIMIC-IV), and 0.879 (95%CI: 0.846-0.912; CHN-dataset). It significantly outperformed APACHE (AUC = 0.740, 95%CI: 0.720-0.761) and SOFA (AUC = 0.717, 95%CI: 0.694-0.740) scores. The model demonstrated strong generalizability across ethnicities, ward types, and genders within MIMIC-IV. Using daily data (DM dataset), predicted IHM risk accurately tracked patient trajectories: risk decreased progressively for survivors and increased for non-survivors throughout the ICU stay. SHAP analysis identified key predictors: NI-SBP, age, heart rate, WBC, glucose, and notably, RDW and MCHC. Time-dependent Cox regression confirmed RDW increase (HR = 3.783, 95%CI: 2.237-6.398) and MCHC decrease (HR = 0.173, 95%CI: 0.040-0.741) as significant independent risk factors for IHM. Conclusions: The developed XGBoost model provides a reliable, generalizable tool for real-time IHM risk quantification and monitoring in ICU HF patients, using only 17 routinely collected clinical variables. It surpasses traditional scoring systems and enables dynamic risk assessment throughout the ICU stay. By identifying patient-specific major risk factors via SHAP values, the model facilitates timely, personalized treatment adjustments.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.